This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fairman, R. P. Articles by Fowler, A. A. Search for Related Content PubMed PubMed Citation Articles by Fairman, R. P. Articles by Fowler, A. A.

Increase of Rat Pulmonary Microvascular Permeability to Albumin by Recombinant Interleukin-2¹

Departments of Internal Medicine [R. P. F., F. L. G., D. B., A. A. F.] and Anatomy [R. E. M.], Medical College of Virginia and McGuire Veterans Administration, Medical Center, Richmond, Virginia 23298

Immunotherapy with the lymphokine interleukin-2 (IL-2), with or without lymphokine activated killer (LAK) cells, offers a new approach to the treatment of solid tumors. Unfortunately, most patients receiving IL-2 and LAK cells develop a "third space syndrome" from a presumed generalized increase of vascular permeability. We have investigated the role of IL-2 on lung fluid balance, by measuring changes in lung water and albumin intake. Rats were injected with IL-2 500,000 U i.p. three times a day for 1 to 4 days. At the completion of the injections, lungs were isolated and perfused, and total lung water (TLW) and ¹²⁵I-albumin uptake were measured. After 1 day of injections, TLW increased from 4.90 ± 0.14 to 5.57 ± 0.34 ml/g dry lung and albumin uptake nearly doubled from 0.47 ± 0.08 to 0.91 ± 0.28 cm³/s/g dry lung x 10^-3. Longer injection periods increased both TLW and albumin uptake further. After 2 days, TLW and albumin uptake were also significantly increased by 160,000 U i.p. three times a day, but not by 40,000 or 10,000 U. To eliminate possible contributions to increased permeability by (a) LAK cells generated in vivo, or (b) circulating leukocytes, we isolated lungs from normal rats and perfused them for 5 min with a cell-free perfusate containing IL-2 (2, 10, or 5 x 10^-3 U/ml) excipient or 0.9% NaCl placebo. TLW was similar in all groups, but albumin uptake was significantly increased by 10,000 and 50,000 U/ml (0.94 ± 0.15 and 0.82 ± 0.16 cm³/s/g dry lung x 10^-3, respectively), but not by 2,000 U/ml. We conclude that lung microvascular albumin permeability is increased following administration of IL-2 in vivo and in vitro. We suggest that LAK cells are not required for the initiation of increased permeability and that IL-2 may have some direct effect on the pulmonary microvasculature.

¹ This work was supported by the following grants: NIH No. HL-00720 (R. P. F.), National Science Foundation No. 21313 (R. E. M.), and Veterans Administration No. 0004 (F. L. G.).

² To whom requests for reprints should be addressed, at MCV Station Box 50, Medical College of Virginia Hospitals, Richmond, VA 23298-0001.

Received 1/22/87. Accepted 4/ 9/87.

This article has been cited by other articles:

				E. Briasoulis and N. Pavlidis Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy Oncologist, April 1, 2001; 6(2): 153 - 161. [Abstract] [Full Text]

				T. KOSHIKA, A. ISHIZAKA, I. NAGATOMI, Y. SUDO, N. HASEGAWA, and T. GOTO Pretreatment with FK506 Improves Survival Rate and Gas Exchange in Canine Model of Acute Lung Injury Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 79 - 84. [Abstract] [Full Text]